Carfilzomib for relapsed or refractory multiple myeloma

Tanimoto, Tetsuya; Tsuda, Kenji; Oshima, Kiyohiro; Mori, Jinichi; Shimmura, Hiroaki

doi:10.1016/s1470-2045(17)30859-8

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well tolerated and causes minimal neurotoxicity. It has demonstrated promising activity in patients with MM who are refractory to bortezomib or immunomodulatory agents [163][164][165]. It can be combined with dexamethasone or other novel agents [164][165][166].…”

Section: Carfilzomibmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

Al-Anazi¹

2019

Update on Multiple Myeloma

View full text Add to dashboard Cite

Multiple myeloma is the second commonest hematologic malignancy. It is characterized by neoplastic proliferation of a single clone of plasma cells in the bone marrow producing a monoclonal immunoglobulin and ultimately causing various complications and organ dysfunction. Over the last 10 years, management of multiple myeloma has dramatically changed due to the introduction of several novel therapies that have improved the disease outcome and prognosis, as well as the quality of life of patients with myeloma due to their safety, tolerability and efficacy. Additionally, the widespread utilization of autologous hematopoietic stem cell transplantation, which is still the standard of care for transplant-eligible patients, and the implementation of new therapeutic strategies such as drug combinations in addition to consolidation and maintenance therapies have resulted in further improvements in response rates and survival in patients with multiple myeloma. This book chapter will be an update on the novel therapies and the recent treatment strategies in myeloma. The role of stem cell treatments in the era of novel therapies will be discussed thoroughly.

show abstract

Section: Carfilzomibmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

Al-Anazi¹

2019

Update on Multiple Myeloma

View full text Add to dashboard Cite

show abstract

“…It is well tolerated and causes minimal neurotoxicity. It has demonstrated promising activity in patients with MM who are R/R to bortezomib or immunomodulatory agents [88][89][90]. It can be combined with dexamethasone or other agents [89][90][91].…”

Section: Carfilzomibmentioning

confidence: 99%

“…It has demonstrated promising activity in patients with MM who are R/R to bortezomib or immunomodulatory agents [88][89][90]. It can be combined with dexamethasone or other agents [89][90][91]. It is under evaluation for patients with newly diagnosed MM [91].…”

Section: Carfilzomibmentioning

confidence: 99%

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Agents and Targeted Therapies

Ka¹

2018

J Stem Cell Biol Transplant

View full text Add to dashboard Cite

Multiple myeloma, the second commonest hematologic malignancy, is characterized by neoplastic proliferation of a single clone of plasma cells in the bone marrow producing a monoclonal immunoglobulin and ultimately causing various complications and organ dysfunction.Over the last 10 years, management of multiple myeloma has dramatically changed due to the introduction of several novel therapies that have improved the disease outcome and prognosis. Also; these agents have improved the quality of life of patients with myeloma due to their safety, tolerability and efficacy. The utilization of autologous hematopoietic stem cell transplantation, which is still the standard of care for transplant eligible patients, as well as the implementation of new therapeutic strategies such as drug combinations in addition to consolidation and maintenance therapies have resulted in further improvements in response rates and survival in patients with multiple myeloma.

show abstract

Carfilzomib for relapsed or refractory multiple myeloma

Cited by 2 publications

References 5 publications

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Agents and Targeted Therapies

Contact Info

Product

Resources

About